|
|
|
11 January 2019
Pat Rosenstiel, Founder and Chairman of the Trade Alliance to Promote Prosperity, discusses HHS's proposal to create an "International Pricing Index" payment model for prescription drugs administered under Medicare Part B, why this proposal is bad for Americans and how it will hurt research and development of new drugs.
0:00
0:00
Related Podcasts
04 April 2025
Sally Pipes, President and CEO of Pacific Research Institute, discusses her recently released book, “The World’s Medicine Chest: How America Achieved Pharmaceutical Supremacy and How to Keep It,” the horrible impacts of price controls, how single-payer healthcare systems fail children and cancer patients, and more.
02 September 2024
Sally Pipes, Founder and President of Pacific Research Institute, discusses the impact of drug price controls under the Inflation Reduction Act (IRA), what it means for research and development of life-saving medicines, and how the IRA's drug pricing provisions will reduce access to new cures and treatments and result in longer wait times for existing medicines.
28 June 2024
Sally Pipes, President and CEO of Pacific Research Institute, discusses how President Biden's price controls will result in prescription drug shortages and discourage innovation, how government mandates and regulations raise insurance costs, and the grim prognosis on Medicare and Medicaid's viability.
03 December 2021
Phil Kerpen, Founder and President of American Commitment, discusses how drug price controls would hurt seniors as they would reduce access to and undermine research and development in life-saving biopharmaceuticals, and why the Build Back Better Act under consideration in Congress is riddled with other disastrous provisions.
14 February 2020
Timothy Lee, Senior Vice President of Legal and Public Affairs at CFIF, discusses the DOJ's civil antitrust lawsuit seeking to block Sabre Corporation's acquisition of Farelogix, Inc., and why imported price controls for drugs is a prescription for failure.
03 May 2019
Phil Kerpen, President of American Commitment, discusses prescription drug prices, the fundamental problems with importing foreign price controls, and the steps Congress can take to improve the system.
